



UWS Academic Portal

A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension

Panagiotou, Marios; K. Johnson, Martin; Louvaris, Zafeiris; Baker, Julien; Church, Alistair; Peacock, Andrew; Vogiatzis, Ioannis

Published in:
Journal of Applied Physiology

DOI:
[10.1152/jappphysiol.00986.2016](https://doi.org/10.1152/jappphysiol.00986.2016)

Published: 29/06/2017

Document Version
Peer reviewed version

[Link to publication on the UWS Academic Portal](#)

Citation for published version (APA):

Panagiotou, M., K. Johnson, M., Louvaris, Z., Baker, J., Church, A., Peacock, A., & Vogiatzis, I. (2017). A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension. *Journal of Applied Physiology*, 123(4), 851-859. <https://doi.org/10.1152/jappphysiol.00986.2016>

General rights

Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 Title: **A study of clinical and physiological relations of daily physical activity in**
2 **precapillary pulmonary hypertension.**

3
4 **Authors:** Marios Panagiotou¹, Martin K. Johnson¹, Zafeiris Louvaris^{2,3}, Julien S.
5 Baker⁴, Alistair C. Church¹, Andrew J. Peacock¹, Ioannis Vogiatzis^{2,4}.

6 **Author contributions:** MP obtained all of the data in the study, performed data
7 analysis and wrote the manuscript. ZL performed accelerometry data analysis. MP, MKJ,
8 ZL, JSB, ACH, AJP and IV contributed substantially to the study design, data
9 interpretation, and editing of the manuscript.

10 **Affiliations:** ¹Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital,
11 Glasgow, UK; ²Faculty of Physical Education and Sports Sciences, National and
12 Kapodistrian University of Athens, Athens, Greece; ³Faculty of Kinesiology and
13 Rehabilitation Sciences, Department of Rehabilitation Sciences KU Leuven, Division of
14 Respiratory Rehabilitation, University Hospitals Leuven, Belgium; ⁴School of Health and
15 Life Sciences, Northumbria University Newcastle, Newcastle Upon-Tyne, UK.

16 **Corresponding author:** Marios Panagiotou; Scottish Pulmonary Vascular Unit,
17 Golden Jubilee National Hospital, Agamemnon Street, Glasgow, G81 4DY, UK; +44 141
18 9515497; mariopanag@gmail.com.

19 **Abstract**

20 Daily physical activity is reduced in precapillary pulmonary hypertension (PH) but the
21 underlying mechanisms are inadequately explored. We sought to investigate clinical and
22 physiological relations of daily physical activity and profile differences between less and
23 more active patients with precapillary PH. A prospective, cross-sectional study of 20
24 patients with precapillary PH who undertook a) a comprehensive clinical assessment, b) a
25 preliminary treadmill test, c) 7-day monitoring of daily walking intensity with triaxial
26 accelerometry and d) a personalized treadmill test corresponding to the individual patient
27 mean daily walking intensity with real-time physiological measurements. Significant
28 clinical correlations with individual patient mean walking intensity ($1.71 \pm 0.27 \text{ m/s}^2$) were
29 observed for log N-terminal pro-brain natriuretic peptide (log-NTproBNP: $r = -.75$,
30 $p < .001$), age ($r = -.70$, $p = .001$), transfer factor for carbon monoxide %predicted ($r = .51$,
31 $p = 0.022$) and 6-minute walk distance ($r = .50$, $p = .026$). Significant physiological
32 correlations were obtained for heart rate reserve ($r = .68$, $p = .001$), quadriceps tissue
33 oxygenation index (Q-StO₂: $r = .58$, $p = .008$), change in Q-StO₂ from rest ($r = .60$, $p = .006$)
34 and ventilatory equivalent for oxygen uptake ($r = -.56$, $p = .013$). Stepwise multiple
35 regression analyses retained log-NTproBNP ($R^2 = 0.55$), heart rate reserve ($R^2 = 0.44$) and
36 Q-StO₂ ($R^2 = 0.13$) accounting for a significant variance in individual walking intensity.
37 Less active patients had greater physical activity-induced cardiopulmonary impairment,
38 worse quadriceps oxygenation profile and compromised health-related quality of life
39 compared to more active patients. These preliminary findings suggest a significant
40 relation between right ventricular and peripheral muscle oxygenation status and reduced
41 daily physical activity in precapillary PH. Further research is warranted to unravel the

42 physiological determinants, establish clinical predictors, and identify beneficial
43 interventions.

44 **New & Noteworthy**

45 Daily physical activity holds promise to be a meaningful, patient-related outcome
46 measure in pulmonary hypertension. In this study, novel findings in a representative
47 sample of patients with precapillary pulmonary hypertension link reduced daily walking
48 activity, as measured by triaxial accelerometry, with compromised right ventricular and
49 pulmonary vascular status, peripheral muscle oxygenation and health-related quality of
50 life. This provides a preliminary insight into the physiological mechanisms and clinical
51 predictors of daily physical activity in precapillary pulmonary hypertension.

52 **Keywords:** pulmonary arterial hypertension, daily physical activity, right ventricle,
53 skeletal muscle oxygenation.

Introduction

Precapillary pulmonary hypertension (PH) comprises primarily pulmonary arterial hypertension (PAH; group 1) and chronic thromboembolic pulmonary hypertension (CTEPH; group 4) and is characterised by progressive elevation of vascular resistance in the precapillary pulmonary vasculature and right heart failure (13). Despite important advances in the understanding and targeted therapy to date, the morbidity and mortality in precapillary PH remain high. Typically, patients suffer progressive dyspnoea, impaired exercise capacity and health-related quality of life (HRQoL), and premature death (1, 13, 37).

Physical activity is defined as the bodily movement produced by the contraction of skeletal muscle that increases energy expenditure above the basal level and can be described by dimensions of intensity, frequency, duration, mode and context (14). Daily physical activity is an important dimension of HRQoL in cardiopulmonary disease (10, 43) and satisfies the core requirement of a meaningful patient-centered endpoint in clinical trials, defined to be a direct measure of how a patient “feels, functions or survives” where “function” refers to the ability to carry out normal daily activities (15). Regular engagement in physical activity is recommended in PH (13). However, research shows significantly reduced daily physical activity in patients with precapillary PH compared to healthy controls and poorer survival in more sedentary patients (21, 36, 39, 45).

The causes of reduced daily physical activity in PH are not adequately explored. Our perception of the underlying mechanisms remains intuitively focused on pulmonary vasculopathy and right ventricular dysfunction and limited to extrapolations from

standardized exercise testing (40), which may not correspond well to daily physical activity (28, 47). Notably, the role of peripheral muscles has not been investigated. This is despite growing evidence of skeletal muscle abnormalities in PAH (31) and recent findings suggesting that estimates of skeletal muscle oxygenation may reflect the pathophysiology of PAH (32, 33). The ability of the usual clinical variables collected in precapillary PH to predict daily physical activity is not well established.

The purpose of this study was therefore to explore the physiological mechanisms and predictors of reduced physical activity in precapillary PH. To this aim, we investigated relations of patient daily walking intensity as measured by accelerometry with a) routine clinical measures and b) cardiopulmonary and peripheral muscle physiological responses during laboratory exercise corresponding to individual daily walking intensities. We also explored differences between lesser and more active patients. We hypothesized that along with pulmonary vasculature and right ventricular status, peripheral muscle function might be a pertinent factor in reducing daily physical activity in precapillary PH.

Materials & Methods

Study Sample

Consecutive patients with stable PAH and technically inoperable (distal) CTEPH who attended the Scottish Pulmonary Vascular Unit between November 2014 and October 2015 were eligible. The diagnosis had been previously established by right heart catheterisation as recommended (13). Clinical stability was defined as a) no hospitalization for precapillary PH and b) no escalation in therapy for PH or diuretics within 3 months. Exclusion criteria were pulmonary endarterectomy or comorbidities

interfering with physical activity and treadmill testing. Approval from the West of Scotland Research Ethics Committee (14/WS/1075) and written consent were obtained.

Initial evaluation

Data were collected on WHO functional class, maximum voluntary ventilation ($MVV = FEV_1 \times 35$) (1) and transfer factor for carbon monoxide (TLCO) corrected for haemoglobin concentration (19). They also completed the patient-reported Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) (25), a well-validated questionnaire for the assessment of HRQoL in PH. CAMPHOR is probably the most widely studied questionnaire in PH and has been shown to predict clinical deterioration in idiopathic PAH and CTEPH (24). However, CAMPHOR questionnaire has not been validated against objective, accelerometry measures of daily physical activity to date.

Finally, N-terminal pro-brain natriuretic peptide (NTproBNP) and 6-minute walk distance (6MWD) were retrieved from the medical record (median interval: 30 days for both).

Preliminary treadmill test

All subjects performed an incremental treadmill test (RAM 770M Treadmil; RAM Medical and Industrial Instruments & Supplies, Padova, Italy operated through the CASE ES Ergospirometry Testing System; GE Healthcare, Freiburg, Germany) at an initial speed of 1.4 km/h that increased by 0.8 km/h every 3 minutes to the limit of tolerance. During the test, minute-by-minute walking intensity was measured in units of acceleration (m/s^2) using a triaxial activity monitor (DynaPort MoveMonitor; McRoberts, Netherlands). In this manner, a range of individualised walking intensities were plotted

121 against treadmill speeds and a predicted equation for walking intensity and corresponding
122 treadmill speed was generated for each patient.

123 Accelerometry

124 Subjects were fitted with DynaPort accelerometers attached to an elastic strap and
125 positioned over the L2 vertebra (an approximation of the body's center of mass) to record
126 their daily walking intensity continuously for 7 days, excluding sleep and water-based
127 activities. Measurements were considered sufficient if a technically acceptable signal was
128 obtained daily for a minimum of 12 consecutive hours, during 5 consecutive days (18,
129 34). The DynaPort is a validated accelerometer that provides reliable measures of
130 physical activity including postures, steps and movement intensities during locomotion,
131 and even under sedentary conditions (5, 37, 46). The intensity with which a person carries
132 out activities of daily living is a unique measure of daily life activity, which is a
133 fundamental part of recommendations for health maintenance (14) and an important
134 aspect of the overall physical activity in chronic lung disease (34). Importantly, walking
135 intensity can be easily and accurately reproduced on the treadmill, thus allowing the
136 study of individual physiological responses during activity in the laboratory setting [17,
137 18].

138 Personalized treadmill test

139 Within 2 weeks, patients underwent a final, three-stage treadmill protocol during
140 which they sequentially: 1) stood still on treadmill, 2) warmed up at a speed of 1.4 km/h,
141 and 3) walked at a predetermined treadmill speed corresponding to their individual daily
142 walking intensity (calculated by using the predicted equation for walking intensity and

treadmill speed generated during the preliminary treadmill test. The duration of each stage was 4 minutes in order to reach a steady physiological state.

Continuous physiological measurements were obtained throughout as described below. The resting and exercise value for all the physiological variables considered for the analysis was the average value of all the acquired data during the last minute of the first and third stage of the personalized treadmill protocol, respectively.

Metabolic profile

Oxygen uptake (VO_2), minute ventilation (V_E) and ventilatory equivalent ratios for oxygen uptake (V_E/VO_2) and carbon dioxide (V_E/VCO_2) were recorded breath-by-breath (CASE ES, GE Healthcare, Freiburg, Germany). Oxyhaemoglobin saturation (SpO_2) was recorded continuously by pulse oximetry (OxywatchTM MD300C63, Beijing Choice Electronic Tech. Co. Ltd, China). Electrocardiography was used to calculate heart rate (HR) reserve (HRR), defined as the difference between age-predicted maximal HR ($220 - \text{age}$) and peak HR (1).

Central hemodynamics

Estimates of stroke volume and cardiac output were measured using impedance cardiography technology (PhysioFlow[®], Manatec Biomedical, France). PhysioFlow uses variations in the transthoracic impedance to a high-frequency (75 kHz), low-amperage (1.8 mA) alternating current across the thorax during cardiac ejection to calculate stroke volume (4) and it has been previously validated (42) and used in PAH (12). Application of six transthoracic electrodes, autocalibration, verification of signal quality and artifact detection were performed as instructed by the manufacturer (4). The PhysioFlow

principle is based on the assumption that variations in impedance to a high-frequency (75kHz), low-magnitude (1.8 mA) alternating current across the thorax during cardiac ejection result in a waveform from which stroke volume (SV) can be calculated. Initially, a SV index (SVI) is calculated at rest by evaluating 30 consecutive heart beats (autocalibration procedure) using the largest impedance difference during systole, the largest rate of change in the impedance signal (contractility index), the thoracic fluid inversion time, heart rate, and the pulse pressure (systolic minus diastolic arterial pressure). Cardiac output is then calculated by multiplying the SVI by body surface area and HR [R-R interval determined on the electrocardiographic (ECG) first derivative]. The system was auto-calibrated before exercise tests on the treadmill. Signal quality was verified by visualizing the ECG tracing and its first derivative ($dECG/dt$) and the impedance waveform (ΔZ) with its first derivative (dZ/dt). If unstable signal recording occurred, the system did not allow the test to proceed, and a new calibration was performed. After shaving and cleaning the skin, two pairs of electrodes were firmly positioned at the left base of the neck and on the back at the xiphoid level for transmitting and receiving electrical currents. Two electrodes were also placed on the chest (V1/V6 position) for the ECG signal. The auto calibration procedure was started after a period of at least 5 minutes during which patients were sitting immobile on a chair. Cardiac output values were stored beat-by-beat.

Quadriceps oxygenation

Quadriceps tissue oxygenation index ($Q-StO_2$), as an expression of the local microvascular oxygenation status, was measured using spatially resolved near infrared

spectroscopy (NIRO-200NX[®], Hamamatsu Photonics KK, Japan). Tissue oxygenation index is essentially the ratio of oxygenated to total tissue hemoglobin concentration expressed as $[\text{oxyhaemoglobin}/(\text{oxyhaemoglobin} + \text{deoxyhaemoglobin})] \times 100$ (%) and represents an index of the dynamic balance between local tissue oxygen delivery and utilisation in health and disease (3, 23). We have previously shown strong correlations between quadriceps tissue oxygenation index (Q-StO₂) and mixed venous oxygen saturation measured in the pulmonary artery in PAH subjects, both at rest and exercise (32, 33).

To measure Q-StO₂, one transcutaneous probe (S-type) housed in a black rubber holder and fixed using a double-sided adhesive tape, was placed on the belly of each vastus lateralis muscle, 10-12 cm above the lateral epicondyle. Briefly, one fiber optic bundle carries the near-infrared light produced by the laser diodes to the tissue of interest, and a second fiber optic bundle returns the transmitted light from the tissue to a photodetector in the spectrometer. The intensity of incident and transmitted light was recorded continuously and, along with the relevant specific extinction coefficients, was used to measure changes in the oxygenation status of hemoglobin + myoglobin (Hb+Mb) and then covered with a black rubber holder and fixed using a double-sided adhesive tape, thus minimizing the intrusion of extraneous light and loss of near-infrared light. The values shown for Q-StO₂ are the average from both legs.

Estimated systemic oxygen delivery was calculated as the product of cardiac output and arterial oxygen content. The latter was calculated as the product of $1.34 \times$ hemoglobin concentration \times %SpO₂. The systemic arteriovenous oxygen content difference (a-vO₂ difference) was calculated by dividing oxygen uptake by cardiac output

(Fick principle) whereas the systemic oxygen extraction ratio was calculated as the ratio of the a-vO₂ difference to arterial oxygen content (18).

Statistical analysis

Data are reported as means \pm SD or median with 95% confidence interval of median. NTproBNP was log-transformed due to positive skewing. Associations of mean daily walking intensity were examined using the Pearson's correlation coefficient. Significant parameters were further tested using stepwise multiple regression analysis. Patients were dichotomised using the median daily walking intensity for an unpaired group comparison using the Mann-Whitney *U*-test. Data were analyzed using the SPSS statistical package (v 20, SPSS Inc., Chicago, IL). The level of significance was set at $p < .05$.

The critical sample size of the study was calculated using Q-StO₂ as the primary variable, based on a previous study which investigated the association between daily walking intensity (also measured by the same activity monitor) and quadriceps muscle oxygenation in 18 COPD patients (18). On the basis of an expected effect size of 0.589 that had been calculated from the mean difference (14.95%) and the corresponding standard deviation (25.38%) of Q-StO₂ (18), the calculated critical sample size to address the objectives of the present study using multiple regression analysis with power of 0.80 and 2-sided alpha significance level of 0.05 (calculated using GPower statistical software, v 3.1; Heinrich Heine University Düsseldorf, Germany) was 18 patients.

Results

Patient characteristics

Patients characteristics are presented in Table 1. Twenty patients were enrolled,

completed the protocol without adverse effects and were included in the analysis (Figure 1). Stroke volume profile of 3 (15%) patients had to be excluded due to invalid impedance cardiography signal. Sixteen patients had PAH (9, idiopathic PAH; 6, connective tissue disease associated-PAH; 1, PAH after correction of congenital heart disease) and 4 patients had CTEPH. None of the patients had previously had a significant cardiac shunt detected at transthoracic echocardiogram, cardiac magnetic resonance imaging or right heart catheterisation. All patients were on PH-specific therapy: 10, monotherapy (7, phosphodiesterase-5 inhibitor (PDEi); 2, stimulator of soluble guanylate cyclase (sGC); 1, endothelin receptor antagonist (ERA)) and 10, combination therapy (6, PDE-i+ERA; 1, ERA+sGC; 3, PDEi+ERA+inhaled prostanoid). None of the patients was on heart rate-limiting medication.

In the preliminary test, the tolerated treadmill speeds ranged between 0.8 and 6.2 km/h corresponding to walking intensities ranged between 1.07 to 3.96 m/s². In the personalized test, the treadmill speeds ranged from 0.8 to 3.3 km/h corresponding to daily walking intensities between 1.08 and 2.22 m/s².

Total and daily time of accelerometry monitoring were 6.4±0.94 days and 864±94 min, respectively. Mean and median daily walking intensity were 1.71±0.27 m/s² and 1.78 (1.55, 1.83) m/s², respectively. Daily walking time was 61±26 min and daily steps were 4897±2209 indicating a generally sedentary lifestyle [43].

Correlations and predictors of daily walking intensity

Significant clinical correlations with mean daily walking intensity were observed for log-NTproBNP (r=-.75, p=<.001), age (r=-.70, p=.001) (Figure 2) and 6MWD (r=.50, p=.026). Significant physiological correlations with mean daily walking intensity were

observed for HRR ($r=.68$, $p=.001$), $Q\text{-StO}_2$, ($r=.58$, $p=.008$), change in $Q\text{-StO}_2$ from rest to mean daily walking intensity ($r=.60$, $p=.006$), V_E/VO_2 ($r=-.56$, $p=.013$) and $TLCO\%$ predicted ($r=.51$, $p=0.022$) (Figure 2). There was no significant association between estimates of stroke volume at rest or exercise and mean daily walking intensity.

Stepwise multivariate regression analysis of significant clinical measures retained log-NTproBNP and age accounting for 75% of the variance in mean daily walking intensity, (Table 3). Repeated for the significant physiological measures, analysis retained HRR and $Q\text{-StO}_2$ at activity accounting for 57% of the variance in mean daily walking intensity (Table 3).

Comparison between less and more active patients

There was no significant difference in VO_2 between less and more active patients. Less active patients had significantly increased age, log-NTproBNP, V_E/MVV , V_E/VO_2 , CAMPHOR score and decreased $TLCO\%$ predicted, HRR, $Q\text{-StO}_2$ at mean daily walking intensity and $Q\text{-}\Delta\text{StO}_2$. They also showed a 100-metre reduction in 6MWD compared to more active patients (Table 1 and 2).

Discussion

This exploratory study in a representative cohort with precapillary PH reports on significant associations of indices of right ventricular (log-NTproBNP, HRR) and pulmonary vascular ($TLCO\%$ predicted) status with mean daily walking intensity. In exercise conditions reproducing individual daily physical activity levels, measures of quadriceps oxygenation ($Q\text{-StO}_2$ at activity, $\Delta Q\text{-StO}_2$) and ventilatory efficiency (V_E/VO_2) were also associated significantly with mean daily walking intensity. Log-

NTproBNP, HRR and Q-StO₂ at mean activity levels predicted a significant proportion of the variance in mean daily walking intensity. Finally, the profile of less active patients comprised greater cardiorespiratory impairment, worse quadriceps oxygenation profile and compromised HRQoL compared to more active patients.

Overall, the present population adopted either a sedentary lifestyle, defined as daily steps of <5000 (43) (12 out of 20 patients; 60%) or a low-active lifestyle, defined as daily steps between 5000 and 7500 (43) (8 out of 20 patients; 40%). Also, mean daily walking intensity in the present cohort (1.71 m/s²) compares with that adopted by older patients with moderate/severe COPD (spirometric classes II/III), typically corresponding to 1.8 m/s² (18, 34). This adds to previous evidence (21, 36, 39, 45) of reduced measures of daily physical activity in precapillary PH.

The hemodynamic profile in precapillary PH depends mostly on right ventricular performance (16). NT-proBNP, a nonspecific marker of myocardial dysfunction, is considered an indicator of the right ventricular status and a prognostic marker at diagnosis and during follow-up in precapillary PH (13). Out of 35 variables, NT-proBNP was also the strongest predictor of peak VO₂ and a significant predictor of 6MWD in patients with chronic heart failure (11). In line, we observed a strong negative correlation between log-NTproBNP and mean daily walking intensity whereas log-NTproBNP predicted more than half of the variance in mean daily walking intensity. It was significantly elevated in less active patients.

Heart rate profiles in precapillary PH are thought to reflect the burden of the right ventricle (16). In the setting of right ventricular failure and fixed/reduced stroke volume response with exercise, patients with precapillary PH become dependent on a

compensatory increase in HR responses to maintain or increase cardiac output and preserve tissue oxygenation (16). Hence, the HR-VO₂ relationship in precapillary PH is left-shifted with submaximal HR values trending higher than normal (1). Accordingly, chronotropic response (peak walking HR minus resting HR) and resting HR in PAH, have been independently associated with 6MWD (35) and prognosis (16), respectively. Here, we extend these findings by showing a strong relation between HRR and mean daily walking intensity and significantly reduced HRR in less active patients compared to more active patients. HRR also predicted almost half of the variance in individual mean daily walking intensity.

Higher HR accounted for the higher cardiac output in less active patients in the present study. Estimates of stroke volume did not differ between less and more active patients and it was dissociated with daily walking activity. Cardiac output also did not correlate with daily walking intensity in the present cohort. Previous studies using right heart catheterisation data also failed to show correlation between cardiac output/index and daily physical activity levels in precapillary PH (21, 36). In contrast, TLCO %predicted, reflecting pulmonary capillary volume, was also negatively associated with mean daily walking intensity and 40% lower in less active patients. Collectively, our findings on NT-proBNP and HRR profiles and TLCO %predicted suggest a significant relation between the right ventricular and pulmonary capillary volume status and daily physical activity in precapillary PH.

The ventilatory response becomes exaggerated in precapillary PH due to chemo/ergo/baro- receptor sensitivity, dead space ventilation and hypoxemic drive.

Premature lactic acidosis at the peripheral muscles due to hypoxemia will also increase the ventilatory drive on activity. Physiologically, the ventilatory response to the metabolic requirement is reflected in the V_E/VO_2 relationship (1). Accordingly, we observed a negative correlation between V_E/VO_2 and mean daily walking intensity and V_E/VO_2 and V_E/MVV were significantly higher among less active patients (by almost 20% and 40%, respectively). V_E/VCO_2 ratio, which is an important index of ventilatory efficiency and prognostic significance in precapillary PH, also differed between the 2 groups (58 vs. 44). However, it did not reach statistical significance, possibly, due to submaximal testing and small sample size. Such an exaggerated ventilatory response is highly relevant to physical activity as it may promote dyspnoea and cessation of exercise.

Patients with PAH exhibit significant morphological and functional changes of the quadriceps muscle including alteration in the muscle fibre type, muscle atrophy, reduced capillarity and oxidative capacity, and endothelial dysfunction (31). These abnormalities may impair the local tissue oxygen delivery and utilization capacity, muscle strength and exercise capacity (20). Muscle characteristics were unrelated to the hemodynamic severity (20) and targeted exercise training reversed abnormalities and improved exercise capacity (6, 26). This suggests that peripheral muscle abnormalities may be implicated independently in the exercise pathophysiology of PAH. Here, $Q\text{-}StO_2$ at activity correlated with mean daily walking intensity, predicted a clinically significant amount of the variance in daily walking intensity, and was significantly lower in less active patients. Of significance, $\Delta Q\text{-}StO_2$ responses contrasted sharply between the patient groups. Less active patients showed a fall in $Q\text{-}StO_2$ whereas more active patients experienced an increase in $Q\text{-}StO_2$ at individual mean daily walking intensity.

Factors determining local muscle oxygenation are modulated by the rate of oxygen delivery and oxygen extraction (8). Whereas arterial oxygen content and systemic oxygen delivery did not differ between the present patient groups, less active patients had significantly reduced a-vO₂ difference and ~ 10% reduction in oxygen extraction ratio compared to more active patients. Collectively, our novel findings on estimates of muscle oxygenation suggest a strong relationship between the capacity to enhance local muscle oxygenation and better preserved daily physical activity and they provide support to the peripheral muscle hypothesis (29). They also add to previous evidence showing: a) impaired oxygen extraction rate during maximal exercise in PAH patients compared to patients with pulmonary venous hypertension (41), b) lower muscle resting StO₂ in PAH compared to CHF and healthy subjects (9), c) greater quadriceps oxygen delivery-to-utilization inequalities ($\Delta[\text{Mb-HHb}]$; change in deoxygenated myoglobin from rest to exercise) in PAH compared to healthy subjects, which accounted for a slower rate of adaptation of aerobic metabolism at exercise (2) and d) reduced quadriceps oxygenation (lower Q- ΔStO_2 , higher $\Delta[\text{Mb-HHb}]$) in PAH compared to normal subjects even during submaximal exercise (22). $\Delta[\text{Mb-HHb}]$ was also related to reduced quadriceps capillarity and strength, and lower VO₂ (22).

Certainly, our study design does not allow for proof of causality and further research is required before a primary impairment of peripheral muscle oxygenation is considered a true limiting factor rather than a mere consequence of deconditioning or reflection of hypoxemia. Nonetheless, we found no association between Q-StO₂ and SpO₂ or arterial oxygen content at rest/exercise ($p > 0.5$ for all). Furthermore, Q- ΔStO_2 and $\Delta[\text{Mb-HHb}]$ in PAH subjects have been previously shown to remain unchanged with oxygen

supplementation (22).

A unifying explanation may lie within the seemingly paradoxical absence of difference in VO_2 between less and more active patients. It is possible that the metabolic requirements of the increased workload (reduced HRR) of the stressed heart (increased log-NTproBNP) and increased/inefficient ventilation (increased V_E/MVV , V_E/VO_2) in less active patients had matched the oxygen requirements of increased daily walking intensity in more active patients. Teleologically, it may be that both patient groups had adjusted their activity to a certain threshold of oxygen/energy cost that allowed for acceptable exertional symptoms such as muscle fatigue and breathlessness (as suggested by responses in ventilation and estimates of quadriceps oxygenation). Ultimately, less active patients showed convincingly compromised HQoL (worse CAMPHOR scores).

The current study is limited by its cross-sectional design, small sample and small number of patients with advanced disease willing to undergo such a complex study protocol. Stroke volume profile of 3 (15%) patients had to be excluded due to invalid impedance cardiography signal but this limitation is inherent to impedance cardiography and this figure is similar to previously published experience in precapillary PH (12). Furthermore, the absence of direct measurement of peripheral muscle strength does not allow for further exploration of the role of the peripheral muscle. Arterial oxygen content was estimated using continuous SpO_2 readings at the expense of possible reduced accuracy in the hypoxaemic patients compared to invasive arterial blood sampling. For patient comfort, measurements of 6MWD and NT-proBNP were retrospective in nature. However, in the context of clinical stability (a prerequisite for patient inclusion in the study), an interval of 30 days is a clinically acceptable collection period for both

measures. With regards to walking intensity, albeit an attractive measure of the most important mode of human physical activity, it ignores physical activities not involving walking. This may have introduced some limitations in the assessment, interpretation and prediction of the overall physical activity. Finally, this study did not investigate the possible impact of specific diseases and drug therapy on muscle function or the effect of unmeasured variables such as environmental, social and personal factors to daily physical activity. These factors might have accounted for the unexplained variance in daily walking intensity and the moderate correlation of 6MWD with daily walking intensity. Of note, CAMPHOR scores did not correlate with daily walking activity. Taken together with previously shown weak-to-moderate correlations of accelerometry data with 6MWD and patient-reported questionnaire scores (39), these findings question the surrogate value of routine clinical tools in the prediction of daily physical activity in precapillary PH.

Conclusions

Daily physical activity holds promise to be a meaningful, patient-related outcome measure in PH. Our preliminary findings suggest a significant relation between estimates of right ventricular status (as assessed by NT-proBNP levels and heart rate responses) pulmonary vascular status (as assessed by TLCO %predicted), peripheral muscle oxygenation and HRQoL with reduced daily walking intensity in precapillary PH. However, further research is warranted to unravel the physiological determinants and establish the clinical predictors of this phenomenon. The role of muscle function in the natural history of precapillary PH merits particular focus as it offers a potential target for effective interventions.

413 **Acknowledgements**

414 We thank Val Irvine, Agnes Crozier, Karon Carson, Rachel Thomson, Kirsty Menzies
415 and Veronica Ferry for their contribution to patient recruitment and administrative
416 assistance.

417 **Disclosures**

418 Marios Panagiotou is the recipient of a European Respiratory Society PAH Long-
419 Term Research Fellowship n° LTRF 2014-3106 supported by an unrestricted grant by
420 GSK. Zafeiris Louvaris is the recipient of a European Respiratory Society Long-Term
421 Research Fellowship n° LTRF 2016-6686. No conflicts exist for the rest of the authors.

422 **Figure Captions**

423 **Figure 1:** Study flow chart. BMI: body mass index; WHO FC: World Health
 424 Organization functional class; PFT: pulmonary function testing; 6MWD: 6-minute walk
 425 distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide. VO_2 :
 426 oxygen uptake; VE: minute ventilation; MI: movement intensity; VE/VO_2 : ventilatory
 427 equivalent ratio for oxygen; VE/VO_2 : ventilatory equivalent ratio for carbon dioxide;
 428 HRR: heart rate reserve; SpO_2 : oxyhaemoglobin saturation; SV: stroke volume; CO:
 429 cardiac output; $Q-StO_2$: quadriceps tissue oxygenation index; $Q-\Delta StO_2$: change in $Q-StO_2$
 430 from rest to exercise. The study protocol for each patient was concluded within 2 weeks.
 431 * Retrospective data (median interval: 30 days); § Resting and exercise value was the
 432 average value obtained during the last minute of the 1st and 3rd stage of the personalised
 433 treadmill test (see text for explanation), respectively; # SV and CO profile of 3 patients
 434 was excluded due to invalid impedance cardiography signal.

435

436 **Figure 2:** Correlations (Pearson's r) between daily walking intensity recorded by
 437 triaxial accelerometer and log N-terminal pro-brain natriuretic peptide (log-NTproBNP)
 438 (A); age (B); heart rate reserve (HRR) (C); ventilatory equivalent ratio for oxygen uptake
 439 (V_E/VO_2) (D); quadriceps tissue oxygenation index ($Q-StO_2$) at activity (E); and change
 440 in $Q-StO_2$ from rest to activity ($Q-\Delta StO_2$) (F) in 20 patients with precapillary pulmonary
 441 hypertension.

442 **Table 1:** Clinical characteristics and comparison between less and more active patients¹

		Daily walking intensity, m/s^2		P-value
Variable	All (n=20)	< 1.78 (n=10)	≥ 1.78 (n=10)	
Walking Intensity, m/s^2	1.71 ± 0.27	1.54 (1.29-1.75)	1.86 (1.79-2.03)	<.001*
Treadmill speed, km/hr	$2.27 \pm .84$	1.90 (1.00-2.90)	2.95 (1.80-3.20)	.037*
Sex, m/f	8/12	4/6	4/6	N/A
Age, yrs	54.1 ± 15.9	66.0 (44.0-73.0)	48.5 (24.0-56.0)	.045*
BMI, kg/m^2	29.9 ± 5.7	28.1 (18.8-31.6)	25.5 (21.3-29.7)	.705
Idiopathic PAH	9	4	5	N/A
CTD-PAH	6	4	2	N/A
CHD-PAH	1	0	1	N/A
CTEPH	4	2	2	N/A
WHO FC, I/II/III	4/12/4	1/5/4	3/7/0	N/A
mean PAP, $mm\ Hg$	45.1 ± 13.3	46.0 (32.0-57.0)	40.0 (28.0-65.0)	.713
CO, L/min	3.8 ± 1.0	3.6 (2.6-4.3)	4.3 (3.3-5.0)	.102
PVR, <i>Wood units</i>	11.1 ± 5.7	12.3 (6.0-13.5)	8.7 (4.8-15.2)	.369

Values are expressed as means \pm SD or median and 95% confidence interval of median. BMI: body mass index; PAH: pulmonary arterial hypertension; CTD-PAH: connective tissue disease associated PAH; CHD-PAH: PAH after correction of congenital heart disease; WHO FC: World Health Organization functional class; PAP, CO and PVR: historical pulmonary arterial pressure, cardiac output and pulmonary vascular resistance, respectively, measured at diagnostic right heart catheterization, prior to the initiation of PH-specific therapy; 6MWD: 6-minute walk distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide; FEV1: force expiratory volume in one second; FVC, forced vital capacity; TLCO: transfer factor for carbon monoxide. *Significant statistical difference between patient group.

Daily physical activity in precapillary PH.

6MWD, <i>m</i>	418 ± 106	361 (298-513)	469 (347-570)	.076
CAMPHOR	23.2 ± 16.8	36.5 (8.0-46.0)	11.5 (0-36.0)	.041*
log-NTproBNP, <i>pg/mL</i>	2.53 ± 0.53	2.99 (2.75-3.29)	2.10 (1.79-2.42)	<.001*
FEV ₁ , %pred.	89.9 ± 19.1	93.0 (80.0-115.5)	91.0 (65.8-98.5)	0.26
FVC, %pred.	112.4 ± 23.2	115.5 (100.3-141.5)	108.0 (90.0-122.3)	0.34
FEV ₁ /FVC	66.5 ± 8.5	69.0 (60.3-72.0)	66.5 (63.3-71.0)	0.62
TLCO, %	51.1 ± 19.2	62.5 (47.9-73.0)	38.0 (29.7-53.6)	0.025

443

444 **Table 2:** Physiological characteristics and comparison between less and more active patients¹.

		Daily walking intensity, m/s^2		P-value
Variable	All (n=20)	< 1.78 (n=10)	≥ 1.78 (n=10)	
SpO ₂ activity, %	89.9 \pm 7.1	86.0 (81.0-95.0)	95.0 (88.0-96.0)	.1
HRR, <i>beats/min</i>	61.8 \pm 26.2	51.0 (9.0-57.0)	78.5 (67.0-91.0)	<.001*
SV rest/activity, <i>ml/beat</i>	66.5 \pm 21.5/ 80.9 \pm 21.6	59.2 (25.0-116.9)/ 74.1 (42.9-137.0)	63.6 (58.3-79.2)/ 78.9 (72.0-91.2)	.664/ .745
CO rest/activity, <i>l/min</i>	5.4 \pm 1.2 8.9 \pm 2.6	5.2 (3.3-7.1) 10.0 (6.8-16.1)	4.8 (4.2-6.7) 7.5 (6.8-9.3)	.495/ .045*
Q-StO ₂ rest/activity, %	64.1 \pm 7.4/ 65.4 \pm 10.6	63.7 (54.6-68.6)/ 60.5 (43.4-74.5)	65.7 (57.9-74.4)/ 71.4 (62.0-76.4)	.496/ .028*
Q- Δ StO ₂ , %	1.3 \pm 6.6	-2.3 (-6.0-1.8)	5.1 (3.2-7.8)	.003*
V _E /MVV, <i>l/min</i>	40.9 \pm 14.3	48.9 (32.2-60.0)	30.5 (25.9-39.6)	.007*
V _E /VO ₂	51.1 \pm 18.8	55.8 (39.8-81.1)	40.6 (34.3-58.2)	.041*
VO ₂ , <i>ml·kg⁻¹·min⁻¹</i>	9.5 \pm 1.4	9.4 (7.5-11.0)	9.7 (7.9-10.5)	.806
V _E /VCO ₂	52.1 \pm 13.6	57.7 (38.4-77.0)	44.0 (40.0-56.7)	.142
Arterial oxygen content, <i>ml/dl</i>	18.1 \pm 1.42	17.3 (16.3-19.1)	19.1 (17.7-19.3)	.1
Systemic oxygen delivery, <i>l/min</i>	1.4 \pm .5	1.6 (1.1-2.6)	1.4 (1.2-1.6)	.556

¹ Values are expressed as means \pm SD or median and 95% confidence interval of median. SpO₂: oxyhaemoglobin saturation; HRR: heart rate reserve; SV: stroke volume; CO: cardiac output; Q-StO₂: quadriceps tissue oxygenation index; Q- Δ StO₂: change in Q-StO₂ from rest to exercise; V_E: minute ventilation; MVV: maximum voluntary ventilation; V_E/VO₂: ventilatory equivalent ratio for oxygen; V_E/VCO₂: ventilatory equivalent ratio for carbon dioxide; VO₂: oxygen uptake; a-vO₂ difference: arterio-venous oxygen content difference. *Significant statistical difference between patient groups.

Daily physical activity in precapillary PH.

Systemic a-vO ₂ difference, <i>mlO₂/100 ml</i>	7.7 ± 1.6	5.9 (5.1-8.3)	8.6 (6.7-9.8)	.017*
Systemic oxygen extraction, %	42 ± 11	35 (28-51)	44 (34-52)	.239

445

446

447

448

449

450 **Table 3:** Independent predictors of walking intensity in the two multivariate linear regression
 451 analyses¹.
 452

	Unstandardised Regression coefficient		95% CI for	Standardised Regression coefficient			Change statistics	
Model 1	B	SE	B	B	P value	R ²	R ² change	F change
Constant	2.901	.171	2.540 to 3.263	-				
log-NTproBNP	-.292	.068	-.436 to -.148	-.557	0.001	.555	-	22.45
Age	-.008	.002	-.013 to -.004	-.485	0.002	.755	.20	13.88
Model 2	B	SE	B	B	P value	R ²	R ² change	F change
Constant	.679	.286	.070 to 1.288	-				
HRR	.006	.002	.001 to 0.11	.506	.015	.436	-	12.38
Q-StO ₂	.010	.005	.000 to .020	.395	.049	.538	.132	9.87

453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473

¹ Model 1 contains clinical characteristics. Model 2 contains physiological characteristics.
 Log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide; HRR: heart
 rate reserve; Q-StO₂: quadriceps tissue oxygenation index.

References

1. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 167: 211-77, 2003.
2. Barbosa PB, Ferreira EM, Arakaki JS, Takara LS, Moura J, Nascimento RB, Nery LE, Neder JA. Kinetics of skeletal muscle O₂ delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension. *Eur J Appl Physiol*; 111 :1851-61, 2011.
3. Boushel R, Langberg H, Olesen J, Gonzales-Alonzo J, Bülow J, Kjaer M. Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. *Scand J Med Sci Sports* 11: 213-22, 2001.
4. Charloux A, Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M, Mettauer B, Geny B, Lonsdorfer J. A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the "direct" Fick method. *Eur J Appl Physiol* 82: 313-20; 2000.
5. de Groot S, Nieuwenhuizen MG. Validity and reliability of measuring activities, movement intensity and energy expenditure with the DynaPort MoveMonitor. *Med Eng Phys* 35: 1499-505, 2013.
6. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, Postmus PE, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J* 34: 669-75, 2009.
7. Deboeck G, Niset G, Vachiery JL, Moraine JJ, Naeije R. Physiological response to the six-minute walk test in pulmonary arterial hypertension. *Eur Respir J* 26: 667-72, 2005.
8. DeLorey DS, Kowalchuk JM, Paterson DH. Relationship between pulmonary O₂ uptake kinetics and muscle deoxygenation during moderate-intensity exercise. *J Appl Physiol (1985)* 95: 113-20, 2003.
9. Dimopoulos S, Tzanis G, Manetos C, Tasoulis A, Mpouchla A, Tseliou E, Vasileiadis I, Diakos N, Terrovitis J, Nanas S. Peripheral muscle microcirculatory alterations in patients with pulmonary arterial hypertension: a pilot study. *Respir Care* 58: 2134-41, 2013.
10. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, Aizpiri S, Aguirre U, Capelastegui A. Impact of changes in physical activity on health-related quality of life among patients with COPD. *Eur Respir J* 36: 292-300, 2010.
11. Felker GM, Whellan D, Kraus WE, Clare R, Zannad F, Donahue M, Adams K, McKelvie R, Piña IL, O'Connor CM; HF-ACTION Investigators. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. *Am Heart J* 158(4 Suppl): S37-44, 2009.
12. Ferreira EM, Ota-Arakaki JS, Barbosa PB, Siqueira AC, Bravo DM, Kapins CE, Silva CM, Nery LE, Neder JA. Signal-morphology impedance cardiography

- during incremental cardiopulmonary exercise testing in pulmonary arterial hypertension. *Clin Physiol Funct Imaging* 32: 343-52, 2012.
13. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J*; 46: 903-75, 2015.
 14. Global Recommendations on Physical Activity for Health. Geneva: World Health Organization; 2010.
 15. Gombert-Maitland M, Bull TM, Saggarr R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. New trial designs and potential therapies for pulmonary artery hypertension. *J Am Coll Cardiol* 62(25 Suppl): D82-91, 2013.
 16. Henkens IR, Van Wolferen SA, Gan CT, Boonstra A, Swenne CA, Twisk JW, Kamp O, van der Wall EE, Schalij MJ, Vonk-Noordegraaf A, Vliegen HW. Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol* 103: 1451-6, 2009.
 17. Kortianou EA, Louvaris Z, Vasilopoulou M, Nasis I, Kaltsakas G, Koulouris NG, Vogiatzis I. Activity monitoring reflects cardiovascular and metabolic variations in COPD patients across GOLD stages II to IV. *Respir Physiol Neurobiol* 189: 513-20, 2013.
 18. Louvaris Z, Kortianou EA, Spetsioti S, Vasilopoulou M, Nasis I, Asimakos A, Zakynthinos S, Vogiatzis I. Intensity of daily physical activity is associated with central hemodynamic and leg muscle oxygen availability in COPD. *J Appl Physiol (1985)* 115: 794-802, 2013.
 19. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J* 26: 720-35, 2005.
 20. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. *Thorax* 65: 113-7, 2010.
 21. Mainguy V, Provencher S, Maltais F, Malenfant S, Saey D. Assessment of daily life physical activities in pulmonary arterial hypertension. *PLoS One* 6: e27993, 2011.
 22. Malenfant S, Potus F, Mainguy V, Leblanc E, Malenfant M, Ribeiro F, Saey D, Maltais F, Bonnet S, Provencher S. Impaired Skeletal Muscle Oxygenation and Exercise Tolerance in Pulmonary Hypertension. *Med Sci Sports Exerc* 47: 2273-82, 2015.

23. Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, Wilson JR. Validation of near-infrared spectroscopy in humans. *J Appl Physiol* (1985) 77: 2740-7, 1994.
24. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Chest* 144: 522-30, 2013.
25. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. *Qual Life Res* 15: 103-15, 2006.
26. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation* 114: 1482-9, 2006.
27. Morris NR, Seale H, Harris J, Hall K, Lin AC, Kermeen F. Gas exchange responses during 6-min walk test in patients with pulmonary arterial hypertension. *Respirology* (Aug 16, 2016). doi: 10.1111/resp.12868.
28. Myers J, Gullestad L, Bellin D, Ross H, Vagelos R, Fowler M. Physical activity patterns and exercise performance in cardiac transplant recipients. *J Cardiopulm Rehabil* 23: 100-6, 2003.
29. Naeije R. Breathing more with weaker respiratory muscles in pulmonary arterial hypertension. *Eur Respir J* 25:6–8, 2005.
30. Okumus G, Aslan GK, Arseven O, Ongen G, Issever H, Kıyan E. The role of an activity monitor in the objective evaluation of patients with pulmonary hypertension. *Clin Respir J* (May 5, 2016). doi: 10.1111/crj.12495.
31. Panagiotou M, Peacock AJ, Johnson MK. Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training? *Pulm Circ* 5: 424-34, 2015.
32. Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, MacKenzie A, McGlinchey N, Baker JS, Church AC, Peacock AJ, Johnson MK. Dynamic near-infrared spectroscopy assessment as an important tool to explore pulmonary arterial hypertension pathophysiology. *Eur Respir J*; 49: 1602161, 2017.
33. Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, MacKenzie A, McGlinchey N, Baker JS, Church AC, Peacock AJ, Johnson MK. Near infrared spectroscopy for the assessment of peripheral tissue oxygenation in pulmonary arterial hypertension. *Eur Respir J* 48: 1224-1227, 2016.
34. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 171: 972-7, 2005.
35. Provencher S, Chemla D, Hervé P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. *Eur Respir J* 27: 114-20, 2006.

36. Pugh ME, Buchowski MS, Robbins IM, Newman JH, Hemnes AR. Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. *Chest* 142: 1391-8, 2012.
37. Rabinovich RA, Louvaris Z, Raste Y, Langer D, Van Remoortel H, Giavedoni S, Burtin C, Regueiro EM, Vogiatzis I, Hopkinson NS, Polkey MI, Wilson FJ, Macnee W, Westerterp KR, Troosters T; PROactive Consortium. Validity of physical activity monitors during daily life in patients with COPD. *Eur Respir J* 42: 1205-15, 2013.
38. Roman A, Barbera JA, Castillo MJ, Muñoz R, Escribano P. Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. *Arch Bronconeumol* 49: 181-8, 2013.
39. Saglam M, Vardar-Yagli N, Calik-Kutukcu E, Arikan H, Savci S, Inal-Ince D, Akdogan A, Tokgozoglu L. Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. *J Phys Ther Sci* 27: 309-12, 2015.
40. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. *Circulation* 104: 429-35 2001.
41. Tolle J, Waxman A, Systrom D. Impaired systemic oxygen extraction at maximum exercise in pulmonary hypertension. *Med Sci Sports Exerc* 40: 3-8, 2008.
42. Tonelli AR, Alnuaimat H, Li N, Carrie R, Mubarak KK. Value of impedance cardiography in patients studied for pulmonary hypertension. *Lung*; 189: 369-75, 2011.
43. Tudor-Locke C, Craig CL, Thyfault JP, Spence JC. A step-defined sedentary lifestyle index: <5000 steps/day. *Appl Physiol Nutr Metab* 38: 100-14, 2013.
44. Tung HH, Jan MS, Lin CY, Chen SC, Huang HC. Mediating role of daily physical activity on quality of life in patients with heart failure. *J Cardiovasc Nurs* 27: 16-23, 2012.
45. Ulrich S, Fischler M, Speich R, Bloch KE. Wrist actigraphy predicts outcome in patients with pulmonary hypertension. *Respiration* 86: 45-51, 2013.
46. van Hees VT, van Lummel RC, Westerterp KR. Estimating activity-related energy expenditure under sedentary conditions using a tri-axial seismic accelerometer. *Obesity (Silver Spring)* 17: 1287-92, 2009.
47. Witham MD, Argo IS, Johnston DW, Struthers AD, McMurdo ME. Predictors of exercise capacity and everyday activity in older heart failure patients. *Eur J Heart Fail* 8: 203-7, 2006.

20 patients

Initial evaluation:

age, BMI,
WHO FC, PFT
CAMPHOR
questionnaire,
6MWD*,
log-NTproBNP*.


**Preliminary
treadmill
Test**

**Accelerometry for
7 days:**
movement intensity
(m/s²) &
step count

**Personalised
treadmill test:**

$\dot{V}O_2^{\S}$, $\dot{V}_{E, \S}$,
 $\dot{V}_{E}/\dot{V}O_2^{\S}$, $\dot{V}_{E}/\dot{V}CO_2^{\S}$,
 HRR^{\S} , $SV^{\S\#}$, $CO^{\S\#}$,
 SpO_2^{\S} , $Q-StO_2^{\S}$, $Q-\Delta StO_2^{\S}$

A.



B.

